Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Buy
54
CVM Quote, Financials, Valuation and Earnings
Last price:
$0.71
Seasonality move
:
26.37%
Day range:
$0.69 - $0.72
52-week range:
$0.49 - $3.23
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.27x
Volume:
84.5K
Avg. volume:
839.5K
1-year change:
-74.55%
Market cap:
$44.7M
Revenue:
--
EPS (TTM):
-$0.58
Analysts' Opinion
-
Consensus RatingCEL-SCI has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, CEL-SCI has an estimated upside of 1004.76% from its current price of $0.70.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.70.
Fair Value
-
According to the consensus of 0 analysts, CEL-SCI has 1004.76% upside to fair value with a price target of -- per share.
CVM vs. S&P 500
-
Over the past 5 trading days, CEL-SCI has underperformed the S&P 500 by -10.17% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
CEL-SCI does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
CEL-SCI has grown year-over-year revenues for 1 quarter straight. In the most recent quarter CEL-SCI reported revenues of --.
Earnings Growth
-
CEL-SCI has grown year-over-year earnings for 0 quarters straight. In the most recent quarter CEL-SCI reported earnings per share of -$0.14.
Enterprise value:
44.3M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-2.31x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2023-06-30 | 2024-06-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$35.6M | -$33M | -$27.7M | -$8.2M | -$6.7M | |
| EBITDA | -$31.3M | -$29M | -$23.7M | -$7.2M | -$5.7M | |
| Diluted EPS | -$0.85 | -$0.77 | -$0.58 | -$0.19 | -$0.14 | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $22.7M | $49.7M | $31M | $7.7M | $3.5M | |
| Total Assets | $42M | $79.6M | $56.9M | $32.3M | $24.1M | |
| Current Liabilities | $4.7M | $5.2M | $4M | $5.3M | $5.5M | |
| Total Liabilities | $23M | $19.8M | $18.2M | $17.5M | $15.6M | |
| Total Equity | $19M | $59.8M | $38.7M | $14.8M | $8.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2023-06-30 | 2024-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$18.1M | -$22.7M | -$19M | -$5.7M | -$4.6M | |
| Cash From Investing | $10.1M | -$378K | -$98.7K | -$196.9K | -$23.5K | |
| Cash From Financing | $148.3K | $156.9K | $14.4M | $951.6K | -$322.3K | |
| Free Cash Flow | -$19.2M | -$23.1M | -$19.1M | -$5.9M | -$4.6M | |
CVM
Sector
Market Cap
$44.7M
$46.1M
Price % of 52-Week High
21.67%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-74.55%
-30.52%
Beta (5-Year)
0.593
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.70
200-day SMA
Sell
Level
$1.19
Bollinger Bands (100)
Sell
Level
0.7 - 1.14
Chaikin Money Flow
Sell
Level
-448.3M
20-day SMA
Buy
Level
$0.65
Relative Strength Index (RSI14)
Buy
Level
50.99
ADX Line
Buy
Level
25.65
Williams %R
Neutral
Level
-65.5132
50-day SMA
Sell
Level
$0.73
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Neutral
Level
276.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Stock Forecast FAQ
In the current month, CVM has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CVM average analyst price target in the past 3 months is --.
-
Where Will CEL-SCI Stock Be In 1 Year?
According to analysts, the consensus estimate is that CEL-SCI share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About CEL-SCI?
Analysts are divided on their view about CEL-SCI share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CEL-SCI is a Sell and believe this share price will drop from its current level to --.
-
What Is CEL-SCI's Price Target?
The price target for CEL-SCI over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CVM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for CEL-SCI is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CVM?
You can purchase shares of CEL-SCI via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CEL-SCI shares.
-
What Is The CEL-SCI Share Price Today?
CEL-SCI was last trading at $0.71 per share. This represents the most recent stock quote for CEL-SCI. Yesterday, CEL-SCI closed at $0.70 per share.
-
How To Buy CEL-SCI Stock Online?
In order to purchase CEL-SCI stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 26
Power Solutions International [PSIX] is down 3.27% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.32% over the past day.
Buy
75
SMLR alert for Dec 26
Semler Scientific [SMLR] is up 0.32% over the past day.
